Letter: Maintenance therapy in myeloma: rish versus benefit. 1975

P Jacobs, and D Dubovsky, and H S King

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012306 Risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome. Relative Risk,Relative Risks,Risk, Relative,Risks,Risks, Relative

Related Publications

P Jacobs, and D Dubovsky, and H S King
June 1975, British medical journal,
P Jacobs, and D Dubovsky, and H S King
July 2007, Nature clinical practice. Oncology,
P Jacobs, and D Dubovsky, and H S King
September 2022, Journal of clinical medicine,
P Jacobs, and D Dubovsky, and H S King
February 2017, Therapeutic advances in hematology,
P Jacobs, and D Dubovsky, and H S King
February 2014, Clinical advances in hematology & oncology : H&O,
P Jacobs, and D Dubovsky, and H S King
June 2007, Leukemia,
P Jacobs, and D Dubovsky, and H S King
September 1978, Hospital practice,
P Jacobs, and D Dubovsky, and H S King
October 2014, Hematology/oncology clinics of North America,
P Jacobs, and D Dubovsky, and H S King
July 1976, The British journal of psychiatry : the journal of mental science,
P Jacobs, and D Dubovsky, and H S King
June 1988, European journal of cancer & clinical oncology,
Copied contents to your clipboard!